Assessment of the Effect of Infliximab on Immunomodulation Properties of Mesenchymal Stem Cells In Vitro

Yasaman Aliasghari Sakha ¹ , Ehsan Ehsani ² * , Elham Roshandel ³, Arsalan Jalili ^3,4, Negar Vahdani ³, Abbas Hajifathali ³ *

Cited by CrossRef: 6

1- Zoehler B, Fracaro L, Boldrini-Leite L, da Silva J, Travers P, Brofman P, Bicalho M, Senegaglia A. HLA-G and CD152 Expression Levels Encourage the Use of Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells as an Alternative for Immunosuppressive Therapy. Cells. 2022;11(8):1339 [Crossref]

2- Cheng F. Comments on: �Perianal Crohn�s disease: clinical implications, prognosis and use of resources�. Rev Esp Enferm Dig. 2023; [Crossref]

3- Cheng F. Comment on “A phase IB/IIA study of ex vivo expanded allogeneic bone-marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn disease.”. Surgery. 2024;175(5):1463 [Crossref]

4- Riss S, Dawoud C. Reply to comments on: “Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study”. Wien Klin Wochenschr. 2024;136(9-10):297 [Crossref]

5- Dimova A, Erceg Ivkošić I, Brlek P, Dimov S, Pavlović T, Bokun T, Primorac D. Novel Approach in Rectovaginal Fistula Treatment: Combination of Modified Martius Flap and Autologous Micro-Fragmented Adipose Tissue. Biomedicines. 2023;11(9):2509 [Crossref]

6- Ye M, Cheng F. Comments on: “Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study”. Wien Klin Wochenschr. 2024;136(9-10):295 [Crossref]